Better biomarkers are needed to ensure early and accurate detection and prognosis of prostate cancer
Prostate cancer is now the most common cancer diagnosed in men in Australia,1 and Australia has one of the highest incidence rates of prostate cancer in the world, with an estimated age-standardised rate of 119.2 per 100 000 men.2 Before 1960, the primary diagnostic test for prostate cancer was the prostatic acid phosphatase test. This was eventually replaced in the 1980s by the prostate-specific antigen (PSA) test.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Australian Institute of Health and Welfare. Cancer in Australia 2017 (AIHW Cat. No. CAN 100; Cancer Series No. 101). Canberra: AIHW, 2017. https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2017/contents/table-of-contents (viewed Mar 2018).
- 2. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence and mortality worldwide in 2012. http://globocan.iarc.fr (viewed Mar 2018).
- 3. Flocks RH, Urich VC, Patel CA, Opitz JM. Studies on the antigenic properties of prostatic tissue. 1. J Urol 1960; 84: 134-143.
- 4. Wang MC, Papsidero LD, Kuriyama M, et al. Prostate antigen: a new potential marker for prostatic cancer. Prostate 1981; 2: 89-96.
- 5. Kuriyama M, Wang MC, Lee CI, et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 1981; 41: 3874-3876.
- 6. Medscape. PSA test is misused, unreliable, says the antigen’s discoverer. Medscape Aug 08, 2014. https://www.medscape.com/viewarticle/828854 (viewed March 2018).
- 7. Harvey P, Basuita A, Endersby D, et al. A systematic review of the diagnostic accuracy of prostate-specific antigen. BMC Urol 2009; 9: 14.
- 8. Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005; 48: 386-399.
- 9. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246.
- 10. Catalona WJ, Richie JP, Goodman PJ, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicentre clinical trial of 6,630 men. J Urol 1994; 151: 1283-1290.
- 11. Pinsky PF, Porok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with a median 15 years follow-up. Cancer 2017; 123: 592-599.
- 12. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) investigators. Lancet 2014; 384: 2072-2035.
- 13. Tsodikov A, Gulati R, Heijnsdijk, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO Trials. Ann Intern Med 2017; 167: 449-455.
- 14. Australian Government Department of Health Standing Committee on Screening. Prostate cancer screening. http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/prostate-cancer-screening? (viewed Apr 2018).
- 15. Olver I, Brooks DA, Esterman A. Cancer biomarkers in Australia. Adelaide: University of South Australia, 2017. http://www.unisa.edu.au/Global/Health/Research/Cancer%20Biomarkers%20in%20Australia%20Report.pdf (viewed Mar 2018).
- 16. Pal RP, Kockelbergh RC, Pringle JH, et al. Immunocytochemical detection of ERG expression in exfoliated urinary cells identifies with high specificity patients with prostate cancer. BJU Int 2016; 117: 686-696.
- 17. Eklund M, Nordström T, Aly M, et al. The Stockholm-3 (STHLM3) model can improve prostate cancer diagnostics in men aged 50-69 yr compared with current prostate cancer testing. Eur Urol Focus 2016; doi:10.1016/j.eurf.2016.10.009 [Epub ahead of print].
- 18. Hille C, Pantel K. Prostate cancer: circulating tumour cells in prostate cancer. Nat Rev Urol 2018; doi:10.1038/nrurol.2018.25 [Epub ahead of print].
- 19. Johnson IRD, Parkinson-Lawrence EJ, Keegan H, et al. Endosomal gene expression: an important new indicator for prostate cancer patient prognosis? Oncotarget 2015; 6: 37919-37929.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Doug Brooks is developing cancer biomarkers for commercialisation with Envision Sciences Pty Ltd.